Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
33 results for "Cancer" and "Endocrine Cancers" and "Leukemia"
The purpose of this study is to test the safety of Hu5F9-G4 alone, or in combination with azacitidine in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Other purposes of this study are to determine the best dose of Hu5F9-G4, the quantity of Hu5F9-G4 in your blood, the side effects it has on your body, and whether or not it can improve your cancer.
The purpose of this clinical research study is to identify an appropriate safe dose of JBH492 that can be given to patients with NHL or CLL who did not improve after treatment with currently available therapies, have had their disease worsen, and/or cannot tolerate currently available therapies. This study will also evaluate how well JBH492 might work in treating your disease and will give us an understanding how your body responds to the study treatment. In order to achieve this, a number of blood and tissue samples will be collected during the study.